GLA
MRNA icon

Great Lakes Advisors’s Moderna MRNA Stock Holding History

Great Lakes Advisors’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,767
Closed -$210K – 878
2024
Q2 		$210K Buy
+1,767
New +$224K ﹤0.01% 797
2023
Q2 		– Sell
-3,129
Closed -$481K – 818
2023
Q1 		$481K Sell
3,129
-103
-3% -$17K ﹤0.01% 645
2022
Q4 		$581K Buy
3,232
+8
+0.2% +$1.31K 0.03% 484
2022
Q3 		$382K Sell
3,224
-17,876
-85% -$2.71M 0.01% 521
2022
Q2 		$3.01M Buy
21,100
+13,828
+190% +$1.98M 0.06% 307
2022
Q1 		$1.25M Sell
7,272
-31,467
-81% -$5.3M 0.02% 424
2021
Q4 		$9.84M Sell
38,739
-362
-0.9% -$106K 0.15% 179
2021
Q3 		$15M Buy
39,101
+7,926
+25% +$2.92M 0.23% 137
2021
Q2 		$7.33M Sell
31,175
-139
-0.4% -$24.8K 0.11% 224
2021
Q1 		$4.1M Buy
+31,314
New +$4.54M 0.07% 290

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Great Lakes Advisors's MRNA Position: Q3 2024 in Review

Great Lakes Advisors sold out of Moderna (MRNA) in Q3 2024, closing a stake of 1,767 shares — an estimated $210K sold.

Great Lakes Advisors first reported a position in MRNA in Q1 2021 and held it in 10 quarters. The position peaked at $15M in Q3 2021. 788 funds tracked by Wall St. Rank hold MRNA as of Q3 2024.

  • Great Lakes Advisors reported no remaining Moderna position as of Q3 2024 after selling out during the quarter.
  • Great Lakes Advisors sold 1,767 Moderna shares in Q3 2024, an estimated $210K.
  • Great Lakes Advisors first reported a position in Moderna in Q1 2021 and held it in 10 quarters.
  • Great Lakes Advisors's Moderna position peaked at $15M in Q3 2021.
  • 788 funds tracked by Wall St. Rank held Moderna as of Q3 2024.

Based on Great Lakes Advisors's 13F filing for Q3 2024, filed 4 Nov 2024.